Exelixis
EXEL
#1695
Rank
โ‚ฌ9.49 B
Marketcap
33,24ย โ‚ฌ
Share price
0.52%
Change (1 day)
71.02%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total debt

Total debt on the balance sheet as of September 2024 : โ‚ฌ0.18 Billion

According to Exelixis's latest financial reports the company's total debt is โ‚ฌ0.18 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Exelixis - Total debt on balance sheet (from 2000 to 2024)

Total debt by year

Year Total debt Change
2023-12-31โ‚ฌ0.17 B-3.08%
2022-12-31โ‚ฌ0.17 B291.59%
2021-12-31โ‚ฌ45.27 M13.44%
2020-12-31โ‚ฌ39.9 M-6.88%
2019-12-31โ‚ฌ42.85 M228.7%
2018-12-31โ‚ฌ13.03 M4.73%
2017-12-31โ‚ฌ12.44 M-93.08%
2016-12-31โ‚ฌ0.17 B-52.96%
2015-12-31โ‚ฌ0.38 B30.23%
2014-12-31โ‚ฌ0.29 B16.73%
2013-12-31โ‚ฌ0.25 B-0.94%
2012-12-31โ‚ฌ0.25 B81.59%
2011-12-31โ‚ฌ0.13 B-10.81%
2010-12-31โ‚ฌ0.15 B182.02%
2009-12-31โ‚ฌ55.57 M-33.98%
2008-12-31โ‚ฌ84.17 M1.15%
2007-12-31โ‚ฌ83.22 M-9.73%
2006-12-31โ‚ฌ92.19 M-26.63%
2005-12-31โ‚ฌ0.12 B15.67%
2004-12-31โ‚ฌ0.10 B23.12%
2003-12-31โ‚ฌ88.23 M24.75%
2002-12-31โ‚ฌ70.72 M27.62%
2001-12-31โ‚ฌ55.41 M249.21%
2000-12-31โ‚ฌ15.86 M20.07%
1999-12-31โ‚ฌ13.21 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
โ‚ฌ20.51 B 10,953.10%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚ฌ24.29 B 12,994.04%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚ฌ36.38 B 19,510.17%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ49.05 B 26,334.21%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ57.63 B 30,961.74%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ34.11 B 18,286.18%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ63.57 B 34,160.07%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ3.39 M-98.17%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ36.91 M-80.11%๐Ÿ‡บ๐Ÿ‡ธ USA